AbbVie Common Stock
NYSE: ABBV - Jun 14
70.55 USD 0.88 (1.26%)
NYSE: ABBV - Jun 14
70.55 USD 0.88 (1.26%)
-
Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page
ABBV STOCK HITS RECORD ALL TIME HIGH
- Thread starter anonymous
- Start date
-
- Tags
- None
Agreeing with yourself again ? Haaa Haaa whadda LOSER
Did you find any friends or a job yet ????
Did you find any friends or a job yet ????
Not sure what the argument is about. ABBV is surging and the future looks bright. If you sold your shares then too bad for you. Stop trying to bring everyone else down.
Stock is doing well, strong pipeline, well respected on Wall Street, Humira continues evolve & thrive. What's your point? Do you just want to prove that you're right? I don't get it.
Look for the stock to climb another 10% by the July. If ABBV has another blowout quarter, look for another 10%. Thanks Ricki.
NO WAY stocks @ $79 by July. Lets not get carried away, you make the real investors and truth tellers look bad. 10 % ? BWAAAA HAAAAA Rick ain't that good !
Stay tuned, we'll check back with you in July!
Yeah OK chief....I'll be here......same bat time same bat channel .
BAW WAH HAA
BAW WAH HAA
You knuckleheads need to give ABBV and Rick some Props.
IF you're employed here consider yourself damn lucky to be working for a premier TRUE Pharma company, that stuck with this oversized/staffed sales force, There are some who do little (MET) and others who are driven hard by management (HCV) Lootz/Haas. Y'all Solvay chumps are dogging is as are you Lazy spoiled Humira legacy reps who drug sells itself. Abbvies pipeline data read-outs and updates are a contributing factor driving stock.ABBV valuation won't go any lower and earnings are rising. These two will keep stock in low to mid $70 range. Rick and ALL corporations/shareholders needs Tax reform and then bring offshore money stateside. Also positive top-line results from on (ABT-494) for RAas and phase II study for Crohn's disease. StocK has an impressive valuation with a favorable P/E F12M (12 month), which stands at 11.84 and trades at a discount to large cap pharmaceuticals industry's P/E F12M of 15.91.Expect earnings to increase 14.62% in 2017 and 18.59% in 2018. The numbers indicate that the stock could see $80-85 range in next 24 months. BULLISH !! Be glad you don't work for Gilead which is tanking BIG LEAGUE !
"GIT" to work and make me MORE $$
IF you're employed here consider yourself damn lucky to be working for a premier TRUE Pharma company, that stuck with this oversized/staffed sales force, There are some who do little (MET) and others who are driven hard by management (HCV) Lootz/Haas. Y'all Solvay chumps are dogging is as are you Lazy spoiled Humira legacy reps who drug sells itself. Abbvies pipeline data read-outs and updates are a contributing factor driving stock.ABBV valuation won't go any lower and earnings are rising. These two will keep stock in low to mid $70 range. Rick and ALL corporations/shareholders needs Tax reform and then bring offshore money stateside. Also positive top-line results from on (ABT-494) for RAas and phase II study for Crohn's disease. StocK has an impressive valuation with a favorable P/E F12M (12 month), which stands at 11.84 and trades at a discount to large cap pharmaceuticals industry's P/E F12M of 15.91.Expect earnings to increase 14.62% in 2017 and 18.59% in 2018. The numbers indicate that the stock could see $80-85 range in next 24 months. BULLISH !! Be glad you don't work for Gilead which is tanking BIG LEAGUE !
"GIT" to work and make me MORE $$
AbbVie Common Stock\
NYSE: ABBV - Jun 22, 11:49 AM EDT
$73.15 USD UP 1.81 (2.54%) YUUUUUUUUUGE !!!!!!!!
I'm sure Trump has something to do wit the rise in price!
This is getting good!!!!!! Hang on it's going to be a great ride. Thanks Rickie